EUCTR2016-003459-31-NO进行中（未招募）1 期
Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - the p53 trial - p53 trial
Helse Bergen, Haukeland University Hospital0 个研究点目标入组 190 人开始时间: 2016年8月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Primary (T2 tumors or Locally advanced breast cancers; LABC) in need of pre-surgical chemotherapy or metastatic breast cancer in need of chemotherapy.
- •-Resistance to endocrine therapy:
- •Either i) estrogen and progesterone negative tumor, or ii) harboring an estrogen and / or progesterone positive tumor where regular endocrine therapies have failed or where the treating physician finds endocrine therapy not indicated.
- •-Prior cancer therapy:
- •Metastatic disease:
- •First line treatment:
- •No prior chemotherapy*. Prior endocrine therapy +/- CDK4/6 inhibitor or mTOR inhibitors is allowed if hormone receptor positive, HER2 negative disease.
- •* Only for patients with TP53 mutated disease. Previous adjuvant chemotherapy, including alkylating agents (cyclophosphamide a.o.) and/or platinum, is allowed if completed >12 months prior to inclusion in the trial.
- •Late-stage disease (approved protocol):
- •i) Prior exposure to and resistance to a taxane regimen**.
- •ii) Prior exposure to and resistance to an anthracycline regimen*** -
- •iii) Previous adjuvant chemotherapy, including alkylating agents (cyclophosphamide a.o.) and/or platinum, is allowed if completed >12 months prior to inclusion in the trial.
- •Primary breast cancer (T2 tumors or LABC):
- •i) Prior exposure to and lack of response to a taxane regimen**.
- •ii) Prior exposure to and lack of response to an anthracycline regimen***
- •*** Mandatory only for patients with TP53 wt tumors.
- •** For HER2 positive breast cancer, previous taxane + anti-HER2 treatment is required.
- •In metastatic breast cancer resistance to taxanes/anthracyclines is defined as progressive disease (PD). In primary breast tumors lack of response is defined as stable disease (SD) after 4 courses of chemotherapy or PD, or SD/PD after initial response, or further taxane/anthracyclines is not possible due to toxicity. Breast cancer relapsing within 12 months subsequent to adjuvant taxanes or anthracyclines is considered resistant and re-exposure is not required prior to inclusion in the trial. This relates also to patients who could not receive proper taxane or anthracycline therapy due to side effects or other medical reasons.
- •-The primary tumor or at least one metastatic lesion must be available for biopsy collection at protocol inclusion. Notably; for patients with primary metastatic breast cancer, TP53 status should be determined in a metastatic deposit; tissue from the primary tumor may not substitute (this relates both to patients with synchronous and metachronous metastatic disease).
- •-Patients must have clinically and/or radiographically documented measurable breast cancer according to RECIST.
- •-WHO performance status 0-1
- •-Known tumor ER, PGR and HER2 status in the current situation, i.e. archival and historic breast cancer tissue can not be used for patients with relapse of the disease. However, patients can be included regardless of hormone receptor and HER2 status; in case such information lacks at inclusion, it may be analysed on the biopsy retrospectively.
- •-Age >18 years
- •-Radiology studies for tumor measurements and ecco cor for cardiac function must be performed within 28 days of commencing treatment per protocol (MRI breast for primary breast cancer and CT thorax/abdomen/pelvis and/or MRI + bone scintigraphy/bone scan for metastatic disease).
- •-Before patient registration, written informed consent must be given according to national and local regulations.
- •-Blood test requirements:
- •-Neutrophils > 1.0 x 109/
排除标准
- •-Co-morbidity that, based on the assessment of the treating physician, may preclude the use of cyclophosphamide at actual doses.
- •-Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •-Pregnant or lactating patients.
- •-Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist.
- •-Active cystitis (to be treated upfront)
- •-Active bacterial infections
- •-Urinary obstruction
- •-Known hypersensitivity towards cyclophosphamide or pegfilgrastim, their metabolites and other ingredients in the drug administration formulation.
- •-Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.
- •-Patients with HER2 positive, metastatic breast cancer in the first line setting (Arm C).
- •-Amendment 2021: Previous platinum or cyclophosphamide chemotherapy
- •(incl. EC90) if completed less than 12 months prior to inclusion in the trial.
研究者
相似试验
已完成
2 期
Problem-solving therapy for breast cancer patients undergoing chemotherapy on an outpatient basisBreast cancerJPRN-UMIN000011190Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University100
招募中
不适用
Treatment of patients with breast cancer or gastrointestinal cancer and chemotherapy-induced polyneuropathia with whole body vibration (Galileo technology)Chemotherapy induced polyneuropathyG62Other polyneuropathiesDRKS00006181Klinik für Tumorbiologie50
尚未招募
不适用
A study on the impact of pharmaceutical care on breast cancer patientsCTRI/2020/07/026688Self funded
已完成
不适用
Breast Cancer Care for patients with metastatic diseaseC50C76C77C78C79C80Malignant neoplasm of breastMalignant neoplasm of other and ill-defined sitesSecondary and unspecified malignant neoplasm of lymph nodesSecondary malignant neoplasm of respiratory and digestive organsSecondary malignant neoplasm of other and unspecified sitesMalignant neoplasm, without specification of siteDRKS00013726niversitätsklinikum Würzburg, Frauenklinik und Poliklinik31
已完成
不适用
Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancerCancer - BreastBreast CancerACTRN12615000161527Hellenic Cooperative Oncology Group1,000